Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > No institutions, IP, Nasdaq, timeline meet

<< Previous

Bullboard Posts

Next >>

Comment by JPkatzon May 05, 2021 11:19pm

142 Views

Post# 33138450

RE:No institutions, IP, Nasdaq, timeline meet

It could be they are all one in the same... More than 3 years ago Dan released a letter to shareholders that said.. "we now have unequivocal validation of our H2S platform, and are well-positioned to conclude a series of transformational partnerships over the next 12-18 months." Guess what??? We've got nothing but dilution and empty promises...

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle